Hikma Pharmaceuticals (LON:HIK) Stock Price Up 7.4% – Here’s Why

Shares of Hikma Pharmaceuticals PLC (LON:HIK) rose 7.4% on Friday . The company traded as high as GBX 2,114 ($28.08) and last traded at GBX 2,084 ($27.68). Approximately 937,337 shares were traded during trading, a decline of 32% from the average daily volume of 1,387,898 shares. The stock had previously closed at GBX 1,941 ($25.78).

Wall Street Analyst Weigh In

A number of brokerages have commented on HIK. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 2,560 ($34.01) price objective on shares of Hikma Pharmaceuticals in a report on Monday, March 10th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th.

Hikma Pharmaceuticals Trading Down 0.7%

The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The business has a fifty day simple moving average of GBX 1,950.89 and a 200 day simple moving average of GBX 2,016.10. The stock has a market capitalization of £5.74 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which was paid on Thursday, May 1st. Shareholders of record on Thursday, March 20th were issued a $0.48 dividend. This represents a yield of 1.8%. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.32. The ex-dividend date of this dividend was Thursday, March 20th. Hikma Pharmaceuticals’s dividend payout ratio is currently 60.84%.

Insider Buying and Selling at Hikma Pharmaceuticals

In other news, insider Victoria Hull sold 2,777 shares of the stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of GBX 1,800 ($23.91), for a total transaction of £49,986 ($66,400.11). Insiders own 30.54% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.